



**THIRD QUARTER 2019
SUPPLEMENTAL FINANCIAL INFORMATION**

OCTOBER 24, 2019

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This presentation of Laboratory Corporation of America Holdings (the “Company”) contains forward-looking statements, including but not limited to statements with respect to estimated 2019 guidance and the related assumptions, the impact of various factors on operating and financial results, expected savings and synergies (including from the LaunchPad initiative and as a result of acquisitions), and the opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including health care reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, the effect of public opinion on the Company’s reputation, adverse results in material litigation matters, the impact of changes in tax laws and regulations, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failures in information technology systems or data security, adverse weather conditions, the number of revenue days in a financial period, challenges in implementing business process changes, employee relations, and the effect of exchange rate fluctuations on international operations.

Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks, and uncertainties that could affect the operating and financial results of the Company is included in the Company’s Form 10-K for the year ended December 31, 2018, and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC. The information in this presentation should be read in conjunction with a review of the Company’s filings with the SEC including information in the Company’s Form 10-K for the year ended December 31, 2018, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

USE OF ADJUSTED MEASURES

The Company has provided in this presentation “adjusted” financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, adjusted EBITDA, free cash flow, and certain segment information. The Company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the Company’s operational performance. The Company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the Company’s financial results with the financial results of other companies. However, the Company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are included in the tables accompanying this presentation.

THIRD QUARTER CONSOLIDATED RESULTS

(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)

| | <u>3Q19</u> | <u>3Q18</u> | <u>% Change</u> |
|---|-----------------|-----------------|---------------------|
| Revenue | \$2,928.5 | \$2,831.3 | 3.4% ⁽³⁾ |
| Adjusted Operating Income ⁽¹⁾⁽²⁾ | \$430.5 | \$429.1 | 0.3% |
| <i>Adjusted Operating Margin</i> | <i>14.7%</i> | <i>15.2%</i> | <i>(50 bps)</i> |
| Adjusted EPS ⁽¹⁾⁽²⁾ | \$2.90 | \$2.74 | 5.8% |
| Operating Cash Flow | \$455.6 | \$251.9 | 80.9% |
| Less: Capital Expenditures | <u>(\$92.6)</u> | <u>(\$97.9)</u> | 5.4% |
| Free Cash Flow | \$363.0 | \$154.0 | 135.7% |

(1) Adjusted operating income and Adjusted EPS exclude amortization, restructuring charges, and special items.

(2) See Reconciliation of non-GAAP Financial Measures on slides 16 – 17.

(3) The increase in revenue was primarily due to acquisitions of 2.8% and organic growth of 2.2% (which includes the negative impact from PAMA of 0.9%), partially offset by the disposition of businesses of 1.3% and negative foreign currency translation of 0.3%.

YEAR-TO-DATE CONSOLIDATED RESULTS

(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)

| | <u>Nine Months Ended 9/30/19</u> | <u>Nine Months Ended 9/30/18</u> | <u>% Change</u> |
|---|--------------------------------------|--------------------------------------|---------------------|
| Revenue | \$8,601.4 | \$8,545.9 | 0.6% ⁽⁴⁾ |
| Adjusted Operating Income ⁽¹⁾⁽²⁾ | \$1,288.8 | \$1,328.4 | (3.0%) |
| <i>Adjusted Operating Margin</i> | <i>15.0%</i> | <i>15.5%</i> | <i>(60 bps)</i> |
| Adjusted EPS ⁽¹⁾⁽²⁾ | \$8.46 | \$8.50 | (0.5%) |
| Operating Cash Flow ⁽³⁾ | \$874.9 | \$819.0 | 6.8% |
| Less: Capital Expenditures | <u>(\$272.0)</u> | <u>(\$257.6)</u> | (5.6%) |
| Free Cash Flow | \$602.9 | \$561.4 | 7.4% |

(1) Adjusted operating income and Adjusted EPS exclude amortization, restructuring charges, and special items.

(2) See Reconciliation of non-GAAP Financial Measures on slides 16 – 17.

(3) Operating cash flow increased by \$45.1 million for the six months ended June 30, 2018 due to the reclassification of tax payments for net share settlements relating to employee stock vesting from operating activities to financing activities.

(4) The increase in revenue was primarily due to growth from acquisitions of 1.6% and organic growth of 1.4% (which includes the negative impact from PAMA of 0.9%), partially offset by the disposition of businesses of 1.7% and negative foreign currency translation of 0.7%.

THIRD QUARTER PRO FORMA SEGMENT RESULTS⁽¹⁾

(DOLLARS IN MILLIONS)

| | <u>3Q19</u> | <u>3Q18</u> | <u>% Change</u> |
|---|------------------|------------------|------------------|
| Revenue | | | |
| LabCorp Diagnostics | \$1,759.2 | \$1,752.0 | 0.4% |
| Covance Drug Development | \$1,175.4 | \$1,081.5 | 8.7% |
| Total Revenue | \$2,928.5 | \$2,831.3 | 3.4% |
| Adjusted Operating Income⁽²⁾⁽³⁾ | | | |
| LabCorp Diagnostics | \$296.3 | \$331.5 | (10.6%) |
| <i>Adjusted Operating Margin</i> | <i>16.8%</i> | <i>18.9%</i> | <i>(210 bps)</i> |
| Covance Drug Development | \$175.0 | \$131.3 | 33.3% |
| <i>Adjusted Operating Margin</i> | <i>14.9%</i> | <i>12.1%</i> | <i>270 bps</i> |
| Unallocated Corporate Expense | (\$40.8) | (\$33.7) | (21.1%) |
| Total Adjusted Operating Income | \$430.5 | \$429.1 | 0.3% |
| <i>Total Adjusted Operating Margin</i> | <i>14.7%</i> | <i>15.2%</i> | <i>(50 bps)</i> |

(1) The consolidated revenue and adjusted operating income are presented net of inter-segment transaction eliminations.

(2) Adjusted operating income excludes amortization, restructuring charges, and special items.

(3) See Reconciliation of Non-GAAP Financial Measures on slides 16 – 17.

YEAR-TO-DATE PRO FORMA SEGMENT RESULTS⁽¹⁾

(DOLLARS IN MILLIONS)

| | <u>Nine Months Ended 9/30/19</u> | <u>Nine Months Ended 9/30/18</u> | <u>% Change</u> |
|---|--------------------------------------|--------------------------------------|------------------|
| Revenue | | | |
| LabCorp Diagnostics | \$5,242.1 | \$5,336.3 | (1.8%) |
| Covance Drug Development | \$3,376.4 | \$3,214.1 | 5.0% |
| Total Revenue | \$8,601.4 | \$8,545.9 | 0.6% |
| Adjusted Operating Income⁽²⁾⁽³⁾ | | | |
| LabCorp Diagnostics | \$952.1 | \$1,071.6 | (11.2%) |
| <i>Adjusted Operating Margin</i> | <i>18.2%</i> | <i>20.1%</i> | <i>(190 bps)</i> |
| Covance Drug Development | \$454.7 | \$362.7 | 25.4% |
| <i>Adjusted Operating Margin</i> | <i>13.5%</i> | <i>11.3%</i> | <i>220 bps</i> |
| Unallocated Corporate Expense | (\$118.0) | (\$105.9) | (11.4%) |
| Total Adjusted Operating Income | \$1,288.8 | \$1,328.4 | (3.0%) |
| <i>Total Adjusted Operating Margin</i> | <i>15.0%</i> | <i>15.5%</i> | <i>(60 bps)</i> |

(1) The consolidated revenue and adjusted operating income are presented net of inter-segment transaction eliminations.

(2) Adjusted operating income excludes amortization, restructuring charges, and special items.

(3) See Reconciliation of Non-GAAP Financial Measures on slides 16 – 17.

SELECT FINANCIAL METRICS

(DOLLARS IN MILLIONS)

| | <u>3Q18⁽³⁾</u> | <u>4Q18</u> | <u>1Q19</u> | <u>2Q19</u> | <u>3Q19</u> |
|---|---------------------------|-------------|-------------|-------------|-------------|
| Total Depreciation | \$76.3 | \$79.5 | \$78.3 | \$77.5 | \$80.6 |
| Total Amortization ⁽¹⁾ | \$54.7 | \$56.2 | \$57.1 | \$60.2 | \$61.7 |
| Total Adjusted EBITDA ⁽²⁾ | \$508.9 | \$477.9 | \$493.1 | \$527.6 | \$513.6 |
| Total Debt to Last Twelve Months Adjusted EBITDA ⁽²⁾ | 3.1x | 3.0x | 3.0x | 3.4x | 3.3x |
| Total Net Debt to Last Twelve Months Adjusted EBITDA ^{(2) (4)} | 2.7x | 2.8x | 2.9x | 3.2x | 3.2x |

(1) Excludes amortization of deferred financing fees.

(2) Adjusted EBITDA excludes restructuring charges and special items. See reconciliation on slide 13.

(3) Leverage ratios include Chiltern Adjusted EBITDA from the twelve months prior to the relevant period on a pro forma basis.

(4) Net debt equals total debt less cash and cash equivalents.

COVANCE DRUG DEVELOPMENT: SELECT FINANCIAL METRICS⁽¹⁾

Trailing Twelve Month (TTM) Results

| | Net Orders | Net Book-to-Bill |
|-------------------------------|---------------|------------------|
| TTM Ending September 30, 2019 | \$5.7 billion | 1.28x |
| TTM Ending June 30, 2019 | \$5.5 billion | 1.26x |
| TTM Ending March 31, 2019 | \$5.3 billion | 1.24x |
| TTM Ending December 31, 2018 | \$5.4 billion | 1.26x |


| | Backlog | Estimated revenue expected to convert from backlog in the next twelve months |
|------------------------------------|----------------|--|
| As of September 30, 2019 | \$10.7 billion | \$4.2 billion |
| As of June 30, 2019 ⁽²⁾ | \$10.3 billion | \$4.1 billion |
| As of March 31, 2019 | \$9.9 billion | \$3.9 billion |
| As of December 31, 2018 | \$9.8 billion | \$3.9 billion |

(1) Results shown include the impact from cancellations and foreign currency translation.


(2) Included backlog from the Envigo transaction of approximately \$190 million.

THIRD QUARTER 2019 REVENUE DISTRIBUTION

Segment Distribution



Geographic Distribution



(1) Revenues recognized in over 30 currencies; the largest foreign currency accounts for less than 10% of total revenue.

THIRD QUARTER 2019 FOREIGN EXCHANGE IMPACT TO REVENUE⁽¹⁾

(DOLLARS IN MILLIONS)

| | <u>Dollars</u> | <u>Year over Year % Growth</u> |
|--|----------------|------------------------------------|
| <u>Consolidated</u> | | |
| Revenue, as Reported | \$2,929 | 3.4% |
| Foreign Exchange Impact | \$9 | 0.3% |
| Revenue, Constant Currency | \$2,938 | 3.8% |
| <u>LabCorp Diagnostics</u> | | |
| Revenue, as Reported | \$1,759 | 0.4% |
| Foreign Exchange Impact | \$1 | 0.0% |
| Revenue, Constant Currency | \$1,760 | 0.4% |
| <u>Covance Drug Development</u> | | |
| Revenue, as Reported | \$1,175 | 8.7% |
| Foreign Exchange Impact | \$9 | 0.8% |
| Revenue, Constant Currency | \$1,184 | 9.5% |

(1) Does not tie due to rounding.

YEAR-TO-DATE 2019 FOREIGN EXCHANGE IMPACT TO REVENUE⁽¹⁾

(DOLLARS IN MILLIONS)

| | <u>Dollars</u> | <u>Year over Year % Growth</u> |
|--|----------------|------------------------------------|
| <u>Consolidated</u> | | |
| Revenue, as Reported | \$8,601 | 0.6% |
| Foreign Exchange Impact | \$56 | 0.7% |
| Revenue, Constant Currency | \$8,658 | 1.3% |
| <u>LabCorp Diagnostics</u> | | |
| Revenue, as Reported | \$5,242 | (1.8%) |
| Foreign Exchange Impact | \$9 | 0.2% |
| Revenue, Constant Currency | \$5,251 | (1.6%) |
| <u>Covance Drug Development</u> | | |
| Revenue, as Reported | \$3,376 | 5.0% |
| Foreign Exchange Impact | \$48 | 1.5% |
| Revenue, Constant Currency | \$3,424 | 6.5% |

(1) Does not tie due to rounding.

2019 FINANCIAL GUIDANCE

| | Prior Guidance (assumes foreign exchange rates effective as of June 30, 2019) | Current Guidance (assumes foreign exchange rates effective as of September 30, 2019) |
|---|---|--|
| Total revenue growth: ⁽¹⁾ | 1.0% – 2.0% | 1.5% – 2.0% |
| LabCorp Diagnostics revenue growth: ⁽²⁾ | (3.0%) – (2.0%) | (1.5%) – (0.5%) |
| Covance Drug Development revenue growth: ⁽³⁾ | 5.5% – 8.5% | 5.5% – 7.5% |
| Adjusted EPS: ⁽⁴⁾ | \$11.10 – \$11.40 | \$11.20 – \$11.30 |
| Free cash flow: | \$950 million – \$1.05 billion | \$950 million – \$1.05 billion |

- (1) Prior guidance included the negative impact from the disposition of businesses of approximately 1.5% and foreign currency translation of 0.5%. Current guidance includes the negative impact from the disposition of businesses of approximately 1.5% and foreign currency translation of 0.6%.
- (2) Prior guidance included the negative impact from the disposition of businesses of approximately 2% and foreign currency translation of 0.2%. Current guidance includes the negative impact from the disposition of businesses of approximately 2% and foreign currency translation of 0.1%.
- (3) Prior guidance included the negative impact from foreign currency translation of 0.9%. Current guidance includes the negative impact from foreign currency translation of 1.3%.
- (4) Excludes the impact from amortization, restructuring charges, and special items.

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES – ADJUSTED EBITDA

(DOLLARS IN MILLIONS)

| | <u>3Q18</u> | <u>4Q18</u> | <u>1Q19</u> | <u>2Q19</u> | <u>3Q19</u> |
|---|----------------|----------------|----------------|----------------|----------------|
| Operating Income | \$343.4 | \$307.7 | \$318.2 | \$335.7 | \$339.9 |
| Add: | | | | | |
| Restructuring and other special charges | 10.0 | 11.6 | 20.6 | 13.6 | 14.2 |
| Other special charges ⁽¹⁾ | 21.1 | 19.4 | 15.5 | 37.4 | 14.7 |
| Depreciation | 76.3 | 79.5 | 78.3 | 77.5 | 80.6 |
| Amortization | 54.7 | 56.2 | 57.1 | 60.2 | 61.7 |
| Equity method income, net | 3.0 | 3.1 | 3.0 | 2.5 | 2.4 |
| EBITDA adjustments to equity method income, net | 0.4 | 0.4 | 0.4 | 0.7 | 0.1 |
| Adjusted EBITDA | <u>\$508.9</u> | <u>\$477.9</u> | <u>\$493.1</u> | <u>\$527.6</u> | <u>\$513.6</u> |

(1) Other special charges as disclosed by the Company in its quarterly earnings releases.

RECONCILIATION OF NON-GAAP INCOME STATEMENT

(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)

| | GAAP | | Non-GAAP | |
|---|-------------------------------------|------------|-------------------------------------|------------|
| | Three Months Ended September 30, | | Three Months Ended September 30, | |
| | 2019 | 2018 | 2019 | 2018 |
| Revenues | \$ 2,928.5 | \$ 2,831.3 | \$ 2,928.5 | \$ 2,831.3 |
| Cost of revenues | 2,111.2 | 2,041.4 | 2,111.2 | 2,035.9 |
| Gross profit | 817.3 | 789.9 | 817.3 | 795.4 |
| Selling, general and administrative expenses | 401.5 | 381.8 | 386.8 | 366.3 |
| Amortization of intangibles and other assets | 61.7 | 54.7 | | |
| Restructuring and other special charges | 14.2 | 10.0 | | |
| Operating income | 339.9 | 343.4 | 430.5 | 429.1 |
| Other income (expense): | | | | |
| Interest expense | (60.5) | (59.4) | (60.5) | (59.4) |
| Equity method income, net | 2.4 | 3.0 | 2.4 | 3.0 |
| Investment income | 2.9 | 2.8 | 2.8 | 2.8 |
| Other, net | 2.7 | 209.8 | 0.1 | 0.4 |
| Earnings before income taxes | 287.4 | 499.6 | 375.3 | 375.9 |
| Provision for income taxes | 66.4 | 180.6 | 89.5 | 93.8 |
| Net earnings | 221.0 | 319.0 | 285.8 | 282.1 |
| Less: Net earnings (loss) attributable to the noncontrolling interest | (0.3) | (0.2) | (0.3) | (0.3) |
| Net earnings attributable to Laboratory Corporation of America Holdings | \$ 220.7 | \$ 318.8 | \$ 285.5 | \$ 281.8 |
| Diluted earnings per common share | \$ 2.25 | \$ 3.10 | \$ 2.90 | \$ 2.74 |
| Weighted average diluted shares outstanding | 98.3 | 102.7 | 98.3 | 102.7 |

RECONCILIATION OF NON-GAAP INCOME STATEMENT

(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)

| | GAAP | | Non-GAAP | |
|---|------------------------------------|------------|------------------------------------|------------|
| | Nine Months Ended September 30, | | Nine Months Ended September 30, | |
| | 2019 | 2018 | 2019 | 2018 |
| Revenues | \$ 8,601.4 | \$ 8,545.9 | \$ 8,601.4 | \$ 8,545.9 |
| Cost of revenues | 6,169.6 | 6,141.9 | 6,169.6 | 6,109.6 |
| Gross profit | 2,431.8 | 2,404.0 | 2,431.8 | 2,436.3 |
| Selling, general and administrative expenses | 1,210.6 | 1,174.0 | 1,143.0 | 1,107.9 |
| Amortization of intangibles and other assets | 179.0 | 175.5 | | |
| Restructuring and other special charges | 48.4 | 36.5 | | |
| Operating income | 993.8 | 1,018.0 | 1,288.8 | 1,328.4 |
| Other income (expense): | | | | |
| Interest expense | (176.3) | (186.0) | (176.3) | (186.0) |
| Equity method income, net | 7.9 | 8.5 | 7.9 | 8.5 |
| Investment income | 4.8 | 4.2 | 4.8 | 4.2 |
| Other, net | (18.2) | 209.1 | (8.2) | (0.3) |
| Earnings before income taxes | 812.0 | 1,053.8 | 1,117.0 | 1,154.8 |
| Provision for income taxes | 214.4 | 328.1 | 280.2 | 279.0 |
| Net earnings | 597.6 | 725.7 | 836.8 | 875.8 |
| Less: Net earnings (loss) attributable to the noncontrolling interest | (0.9) | 0.1 | (0.9) | 0.1 |
| Net earnings attributable to Laboratory Corporation of America Holdings | \$ 596.7 | \$ 725.8 | \$ 835.9 | \$ 875.9 |
| Diluted earnings per common share | \$ 6.04 | \$ 7.04 | \$ 8.46 | \$ 8.50 |
| Weighted average diluted shares outstanding | 98.8 | 103.1 | 98.8 | 103.1 |

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES⁽¹⁾

(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|-----------------|------------------------------------|-------------------|
| | 2019 | 2018 | 2019 | 2018 |
| Adjusted Operating Income | | | | |
| Operating Income | \$ 339.9 | \$ 343.4 | \$ 993.8 | \$ 1,018.0 |
| Amortization of intangibles and other assets ^(a) | 61.7 | 54.7 | 179.0 | 175.5 |
| Restructuring and other special charges ^(b) | 14.2 | 10.0 | 48.4 | 36.5 |
| Acquisition and disposition-related costs ^(c) | 9.6 | 5.5 | 53.9 | 43.1 |
| LaunchPad system implementation costs ^(d) | 2.4 | 3.1 | 7.4 | 7.3 |
| Consulting fees and executive transition expenses ^(e) | 5.3 | (0.2) | 8.2 | 4.3 |
| Costs related to ransomware attack ^(f) | — | 12.6 | 0.7 | 12.6 |
| Costs related to data breach ^(g) | 11.3 | — | 11.3 | — |
| Adjustment to acquisition contingent consideration ^(h) | (13.9) | — | (13.9) | — |
| Special tax reform bonus for employees ⁽ⁱ⁾ | — | — | — | 31.1 |
| Adjusted operating income | <u>\$ 430.5</u> | <u>\$ 429.1</u> | <u>\$ 1,288.8</u> | <u>\$ 1,328.4</u> |
| Adjusted Net Income | | | | |
| Net Income | \$ 220.7 | \$ 318.8 | \$ 596.7 | \$ 725.8 |
| Impact of adjustments to operating income | 90.6 | 85.7 | 295.0 | 310.4 |
| Gains and losses on venture fund investments, net ^(j) | (5.8) | — | (1.9) | — |
| (Gain) and loss on sale of business ^(k) | 3.1 | (209.4) | 11.9 | (209.4) |
| Tax reform adjustments ^(l) | — | 28.1 | — | 44.1 |
| Income tax impact of adjustments ^(m) | (23.1) | 58.6 | (65.8) | 5.0 |
| Adjusted net income | <u>\$ 285.5</u> | <u>\$ 281.8</u> | <u>\$ 835.9</u> | <u>\$ 875.9</u> |
| Weighted average diluted shares outstanding | 98.3 | 102.7 | 98.8 | 103.1 |
| Adjusted net income per share | \$ 2.90 | \$ 2.74 | \$ 8.46 | \$ 8.50 |

(1) Footnotes associated with Reconciliation of Non-GAAP Financial Measures are presented on slide 17.

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES – FOOTNOTES

- (a) Amortization of intangible assets acquired as part of business acquisitions.
- (b) Restructuring and other special charges represent amounts incurred in connection with the elimination of redundant positions within the organization in connection with our LaunchPad initiatives and acquisitions or dispositions of businesses by the Company.
- (c) Acquisition and disposition-related costs include due-diligence legal and advisory fees, retention bonuses and other integration and disposition related activities in connection with contemplated and completed transactions.
- (d) LaunchPad system implementation costs include non-capitalized costs associated with the implementation of a system as part of the LaunchPad business process improvement initiative.
- (e) Represents executive transition expenses related to various management reorganizations.
- (f) Costs related to ransomware attack including incremental consulting and employee costs incurred to remediate the impact of a ransomware attack, which occurred during the third quarter of 2018.
- (g) Costs related to the response and remediation of a previously announced vendor data breach, which occurred in the second quarter of 2019.
- (h) During the third quarter of 2019, the Company settled a contingent purchase price for an acquisition, which occurred in the second quarter of 2019.
- (i) During 2018, the Company paid a special one-time bonus to its non-bonus eligible employees in recognition of the benefits the Company is receiving from the passage of the Tax Cuts and Jobs Act of 2017 (TCJA).
- (j) The Company makes venture fund investments in companies or investment funds developing promising technology related to its operations. The Company recorded net gains and losses for the quarter and year-to-date periods related to several distributions from venture funds, increases in the market value of investments, and impairments of other investments due to the underlying performance of the investments.
- (k) Represents the loss on sale of the CRP business as part of the Envigo transaction during the second quarter of 2019 and the gain on sale of the Food Solutions business, which occurred during the third quarter of 2018.
- (l) During 2018, the Company recorded a net increase in its provision for income taxes primarily relating to the repatriation tax associated with the adoption of the TCJA.
- (m) Income tax impact of adjustments calculated based on the tax rate applicable to each item.